Skip to main content
INNOGENE Co., Ltd. logo

INNOGENE Co., Ltd. — Investor Relations & Filings

Ticker · 344860 ISIN · KR7344860002 KO Manufacturing
Open in API
Filings indexed 144 across all filing types
Latest filing 2023-02-10 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 344860

About INNOGENE Co., Ltd.

http://eng.innogene.com

INNOGENE Co., Ltd. is a company specializing in anti-aging solutions. It develops, manufactures, and distributes advanced therapeutic products and cosmetics focused on skin regeneration and hair follicle health. The company's research and development leverages core technologies in medical informatics and a stem cell database to create its product portfolio. These solutions are designed to address concerns related to skin aging and hair loss, based on scientific studies of stem cell applications and healthy beauty.

Recent filings

Filing Released Lang Actions
유상증자또는주식관련사채등의청약결과(자율공시)(일반공모 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a public offering (paid-in capital increase) for the company InnoGen. It details the subscription results, including the number of shares subscribed by institutional and retail investors, the subscription rate, and the schedule for payment and listing. This falls under the category of share issuance and capital changes.
2023-02-10 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) and is explicitly labeled as a 'Correction Report' (정정신고). It details changes to the offering price, capital usage, and subscription methods for a public offering (IPO). This falls under the category of announcements regarding new share issues or capital changes.
2023-02-08 Korean
유상증자최종발행가액확정(일반공모)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the finalization of the issue price for a capital increase (paid-in capital increase/rights offering) by the company InnoGene. It specifies the number of shares, the final price per share, and the date of determination. This falls under the category of share issuance and capital changes.
2023-02-08 Korean
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 98% confidence The document is a '증권신고서(지분증권) 정정신고서' (Amendment to Securities Registration Statement) for Innogene Co., Ltd. It details the finalization of the public offering price (from a range of 2,500-3,000 KRW to a fixed price of 3,000 KRW) and updates the associated offering terms. In the context of financial filings, a document that amends the terms of a securities offering, specifically regarding pricing and share allocation, is classified as a Regulatory Filing (RNS) as it serves as a formal update to the regulatory body (Financial Services Commission) regarding the offering process.
2023-02-08 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 95% confidence The document is a 'Correction Report' (정정신고서) for a 'Securities Registration Statement' (투자설명서) filed by InnoGene. It details changes to the public offering price (from a range of 2,500-3,000 KRW to a fixed price of 3,000 KRW) and related adjustments to the total offering amount and share allocation. This is a formal regulatory filing related to a capital raise/IPO process. Since it is a specific regulatory document regarding the amendment of a securities registration statement, it falls under the 'Regulatory Filings' category.
2023-02-08 Korean
투자설명서
Capital/Financing Update Classification · 95% confidence The document is a 'Investment Prospectus' (투자설명서) for InnoGene Co., Ltd., detailing a public offering of common shares. It includes specific offering details such as the number of shares, offering price range, subscription period, and payment date. It also contains a comprehensive 'Risk Factors' section (핵심투자위험) typical of a formal securities registration statement (증권신고서) filed with the Financial Supervisory Service (DART). This document is a primary offering document for investors, which falls under the category of Proxy Solicitation & Information Statement (PSI) in the context of providing detailed information for investment decisions and regulatory compliance.
2023-02-06 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.